Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancerrelated deaths in the United States. Although chemotherapeutic regimens such as gemcitabine+ nab-paclitaxel and FOLFIRINOX (FOLinic acid, 5-Fluroruracil, IRINotecan, and Oxaliplatin) significantly improve patient survival, the prevalence of therapy resistance remains a major roadblock in the success of these agents. This review discusses the molecular mechanisms that play a crucial role in PDAC therapy resistance and how a better understanding of these mechanisms has shaped clinical trials for pancreatic cancer chemotherapy. Specifically, we have discussed the metabolic alterations and DNA repair mechanisms observed in PDAC and current approaches in targeting these mechanisms. Our discussion also includes the lessons learned following the failure of immunotherapy in PDAC and current approaches underway to improve tumor\u27s immunological response

15th Annual Pancreatic Cancer and Related Diseases Patient Symposium

On Saturday, November 14, 2020, patients/survivors and their friends and family logged in from 167 different locations to join our multi-disciplinary team for our 15th Annual (1st Virtual!) Symposium. The group discussed the latest in medical therapies, surgical options, and innovative research for pancreatic cancer. PROGRAM Welcome and Program Overview Charles J. Yeo, MD, FACS Samuel D. Gross Professor and Chair of Surgery Report of the 2019-2020 Annual Jefferson Pancreas Tumor Registry Survey Theresa P. Yeo, PhD, MPH, MSN, AOCNP Adjunct Associate Professor and Co-Director Jefferson Pancreas Tumor Registry Clinical Trials in Pancreatic Cancer Harish Lavu, MD, FACS Professor of Surgery Section Chief, Hepatopancreatobiliary Surgery Co-Director, Jefferson Pancreas Tumor Registry Recent Data on Adjuvant and Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Atrayee Basu Mallick, MD Clinical Assistant Professor of Medical Oncology Moving Research Forward: Promising Work Amid COVID-19 Aditi Jain, PhD Research Instructor Questions & Answers W. Kim Foster Pancreatic Cancer Pilot Grant Recognition Survivor Tribute Photo & Survivor Testimonia

18th Annual Pancreatic Cancer and Related Diseases Patient Symposium

On November 11, 2023, Charles J. Yeo, MD, FACS, and the multidisciplinary team of clinicians and scientists hosted the 18th Annual Pancreatic Cancer & Related Diseases Patient Symposium. View the Event Photo Gallery View our Pancreatic Cancer Program 2023 Update to learn more about Dr. Yeo and the team’s great work! PROGRAM Welcome and Program OverviewCharles J. Yeo, MD, FACSSamuel D. Gross Professor and Chair of Surgery, Co-Director, Jefferson Pancreas, Biliary, and Related Cancer Center The Jefferson Pancreas Tumor Registry: 2022-2023 Annual UpdateEika Barriera-Justiniano, CRNPDepartment of Surgery Nicole Pocetti, CRNPDepartment of Surgery Patient Support and Programming at SKCCGreg Garber, MSW, LCSWAdministrative Director, Division of Supportive Oncology, Sidney Kimmel Cancer Center Katie Lundy, MSW, LSWOncology Social Worker, Division of Supportive Oncology, Jefferson Health-Asplundh Cancer Pavilion Targeting BARD1 in Pancreatic Cancer: “Expanding BRCAness”Aditi Jain, PhDResearch Assistant Professor, Department of Surgery Advanced Endoscopy: Leaping ForwardDavid Kastenberg, MDJ. Edward Berk Professor of Medicine and Chief, Division of Gastroenterology and Hepatology Clinical Trials Update: Antibiotics in Pancreatic SurgeryHarish Lavu, MD, FACSProfessor of Surgery and Section Chief, Hepatopancreatobiliary Surgery and Director, Jefferson Pancreas Tumor Registry What About My Gut...?James A. Posey, III, MDProfessor of Medicine and Director, Gastrointestinal Program of Medical Oncology and Co-Director, Jefferson Pancreas, Biliary, and Related Cancer Center A Patient’s StoryShawn Johnson Survivor Tribute Phot